EE200000346A - Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidel - Google Patents

Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidel

Info

Publication number
EE200000346A
EE200000346A EEP200000346A EEP200000346A EE200000346A EE 200000346 A EE200000346 A EE 200000346A EE P200000346 A EEP200000346 A EE P200000346A EE P200000346 A EEP200000346 A EE P200000346A EE 200000346 A EE200000346 A EE 200000346A
Authority
EE
Estonia
Prior art keywords
treatment
men
dyssynergy
urinary
study
Prior art date
Application number
EEP200000346A
Other languages
English (en)
Estonian (et)
Inventor
Santti Risto
Talo Antti
Streng Tomi
Halonen Kaija
Kangas Lauri
Lammintausta Risto
Original Assignee
Hormos Medical Oy Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Oy Ltd. filed Critical Hormos Medical Oy Ltd.
Publication of EE200000346A publication Critical patent/EE200000346A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
EEP200000346A 1997-12-12 1998-12-09 Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidel EE200000346A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/989,447 US5972921A (en) 1997-12-12 1997-12-12 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
PCT/FI1998/000954 WO1999030708A2 (en) 1997-12-12 1998-12-09 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents

Publications (1)

Publication Number Publication Date
EE200000346A true EE200000346A (et) 2001-10-15

Family

ID=25535123

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000346A EE200000346A (et) 1997-12-12 1998-12-09 Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidel

Country Status (17)

Country Link
US (2) US5972921A (ja)
EP (1) EP1043993B1 (ja)
JP (1) JP2002508322A (ja)
KR (1) KR20010032909A (ja)
CN (1) CN1281361A (ja)
AT (1) ATE235904T1 (ja)
AU (1) AU743196B2 (ja)
BR (1) BR9813534A (ja)
CA (1) CA2312347A1 (ja)
DE (1) DE69813025T2 (ja)
EE (1) EE200000346A (ja)
ES (1) ES2191358T3 (ja)
HU (1) HUP0100762A3 (ja)
NO (1) NO20002960L (ja)
NZ (1) NZ504632A (ja)
PL (1) PL341653A1 (ja)
WO (1) WO1999030708A2 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
BR0013272B1 (pt) 1999-08-13 2013-10-15 Uso de um inibidor de aromatase esteroidal
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
SK14612002A3 (sk) * 2000-04-12 2003-05-02 Novartis Ag Farmaceutická kompozícia obsahujúca inhibítor aldosterónsyntázy prípadne v kombinácii s antagonistom AT1-receptora a jej použitie
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
FI20010905A0 (fi) * 2001-05-02 2001-05-02 Vetcare Oy Uusi eläinlääke
US6607755B2 (en) 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
US6931276B2 (en) * 2002-04-29 2005-08-16 Tomi Streng Method and device for use in micturition studies
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP1656129A4 (en) * 2003-08-22 2009-03-11 Univ Virginia MTOR BLOCUS FOR PREVENTING HORMONE ADAPTIVE RESPONSE
CN101448490A (zh) * 2006-05-22 2009-06-03 霍尔莫斯医疗有限公司 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂
BR112014005434B1 (pt) * 2011-09-08 2021-01-05 Novartis Ag Composições farmacêuticas compreendendo inibidor da aromatase 4,4'-[fluoro-(1h-1,2,4triazol-1-il)metilemo]bisbenzonitrila e seu método de preparação
CN102641502A (zh) * 2012-04-25 2012-08-22 中国农业大学 芳香酶抑制剂的新用途
JP6545185B2 (ja) * 2014-03-21 2019-07-17 ドン・ワ・ファーム・カンパニー・リミテッドDong Wha Pharm. Co., Ltd. インドナガコショウ抽出物を含む排尿障害の予防、治療及び改善用組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men

Also Published As

Publication number Publication date
CA2312347A1 (en) 1999-06-24
EP1043993B1 (en) 2003-04-02
JP2002508322A (ja) 2002-03-19
NO20002960D0 (no) 2000-06-09
BR9813534A (pt) 2000-11-14
HUP0100762A3 (en) 2002-12-28
US5972921A (en) 1999-10-26
DE69813025T2 (de) 2004-01-15
AU743196B2 (en) 2002-01-24
DE69813025D1 (de) 2003-05-08
ES2191358T3 (es) 2003-09-01
US6316431B1 (en) 2001-11-13
KR20010032909A (ko) 2001-04-25
EP1043993A2 (en) 2000-10-18
WO1999030708A3 (en) 1999-08-19
NO20002960L (no) 2000-08-14
ATE235904T1 (de) 2003-04-15
WO1999030708A2 (en) 1999-06-24
HUP0100762A2 (hu) 2001-08-28
CN1281361A (zh) 2001-01-24
PL341653A1 (en) 2001-04-23
AU1489799A (en) 1999-07-05
NZ504632A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
EE200000346A (et) Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidel
DK0748190T3 (da) Progestogenfrie formuleringer af GnRH og estrogen til behandling af benigne gynækologiske lidelser
AU6093201A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1009755A4 (en) STEROID SULFATASE INHIBITORS AND METHODS OF PRODUCING AND USING THE SAME
NO20053626L (no) Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
NO20030954D0 (no) Fremgangsmåte for å öke testosteron og beslektede konsentrasjoner av steroid hos kvinner
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
WO2002019982A3 (en) Cosmetic composition and method for reducing or preventing wrinkling
AU2001251730A1 (en) Polybutadiene and polyisoprene based theremosetting compositions and method of manufacture
AU6030999A (en) Method of delivering therapeutic agents to the urethra and an urethral suppository
FR2791885B1 (fr) Procede de teinture d'oxydation utilisant un cetose a titre d'agent reducteur et une laccase a titre d'agent oxydant
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
MXPA04003977A (es) Baja concentracion de peroxido para tratamiento o prevencion de infecciones vaginales.
MXPA02009744A (es) Uso de fulvestrant en el tratamiento de cancer resistente de mama.
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
EP0841933A4 (en) BOWMAN BIRK INHIBITOR COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES
AU7394601A (en) Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability
CA2421302A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
AU2222102A (en) Topical composition and method for treating urinary stress incontinence
AU2001262378A1 (en) Method for treating cryptorchidism
EP1142584A4 (en) COMPOSITIONS FOR THE TREATMENT OF COMMON URBANISM AND URINE CONTINENCE